2 completed. 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Stendhal Americas, S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Assessment of Pharmacokinetic Gemigliptin and Metformin Interactions in Healthy Mexican Volunteers Gemigliptin, Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day, Metformin - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Stendhal Americas, S.A. | 34 | 2016-01-15 | 2017-10-16 |
| Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension Fimasartan, Fimasartan; Hydrochlorothiazide - Hypertension, Essential | Phase 3 | Completed | Stendhal Americas, S.A. | 272 | 2013-04-01 | 2015-06-09 |
Diabetes Mellitus, Type 2 (1) · Essential Hypertension (1)
Hydrochlorothiazide (1) · LC15-0444 (1) · Metformin (1) · fimasartan (1)
Mexico (2)
Ignacio Conde-Carmona, M.D. (1) · Ignacio Conde-Carmona, MD (1)
PMID 15539615, PMID 21910510, PMID 22381711, PMID 22608107, PMID 23344912, PMID 23932463, PMID 30249366